Mauna Kea Technologies Reports Full Year 2023 Results and Q1 2024 Sales

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its financial results for the full year 2023 and its sales for the first quarter 2024. For full year 2023, total Group sales increased by 42% to €10.5m, driven by the strong volume growth of the PPU business in the U.S. and the substantial contribution of licensing s